Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)

Authors: Chee Khoon Lee, PhD, Bin-Chi Liao, MD, Shalini Subramaniam, MMed (Clin Epi), Chao-Hua Chiu, MD, Antony J. Mersiades, MMed (Clin Epi), Chao-Chi Ho, MD, PhD, Chris Brown, MBiostats, Chun-Liang Lai, MD, PhD, Brett G.M. Hughes, M.B.B.S. (Hons), Tsung-Ying Yang, MD, PhD, Ken O’Byrne, MD, Yung-Hung Luo, MD, PhD, Sonia Yip, PhD, Ching-Liang Ho, MD, Victoria Bray, PhD, Wu-Chou Su, MD, PhD, Melissa Moore, PhD, Wei-Lien Feng, MS, Ya-Ying Bai, MS, Kate Ford, MHSc, Michelle M. Cummins, PhD, Martin R. Stockler, MSc (Clin Epi), Benjamin J. Solomon, PhD, Thomas John, PhD, James Chih-Hsin Yang, MD, PhD

Source: JTO Clinical and Research Reports, Vol 6, Iss 2, Pp 100771- (2025)

Subject Terms: Non-small cell lung cancer, EGFR mutation, Checkpoint inhibitors, Chemotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364324001413; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/a205a5dab210427083847c139219eada

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis

Authors: Shang‐Gin Wu, Chao‐Chi Ho, James Chih‐Hsin Yang, Shu‐Han Yu, Yen‐Feng Lin, Shu‐Chin Lin, Bin‐Chi Liao, Ching‐Yao Yang, Yen‐Ting Lin, Chong‐Jen Yu, Ya‐Ting Chuang, Wei‐Yu Liao, Kah Yi Yap, Weng Si Kou, Jin‐Yuan Shih

Source: Clinical and Translational Medicine, Vol 15, Iss 1, Pp n/a-n/a (2025)

Subject Terms: anti‐angiogenesis, atezolizumab, EGFR TKI resistance, immune cell, tumour microenvironment, Medicine (General), R5-920

File Description: electronic resource

Relation: https://doaj.org/toc/2001-1326

Access URL: https://doaj.org/article/6baafecd35de4b68b2b1383f366ecc9b

Registry of Genetic Alterations of Taiwan Non–Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521

Authors: Bin-Chi Liao, Nai-Jung Chiang, Gee-Chen Chang, Wu-Chou Su, Yung-Hung Luo, Inn-Wen Chong, Tsung-Ying Yang, Chun-Liang Lai, Te-Chun Hsia, Ching-Liang Ho, Kang-Yun Lee, Chin-Fu Hsiao, Fan-Chen Ku, Wei-Tse Fang, James Chih-Hsin Yang

Source: JCO Global Oncology, Iss 10 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2687-8941

Access URL: https://doaj.org/article/e503bb76a5e74e31a0d489729debaa21

Expert Consensus on Molecular Tumor Boards in Taiwan: Joint Position Paper by the Taiwan Oncology Society and the Taiwan Society of Pathology

Authors: Ming-Huang Chen, Wan-Shan Li, Bin-Chi Liao, Chiao-En Wu, Chien-Feng Li, Chia-Hsun Hsieh, Feng-Che Kuan, Huey-En Tzeng, Jen-Fan Hang, Nai-Jung Chiang, Tse-Ching Chen, Tom Wei-Wu Chen, John Wen-Cheng Chang, Yao-Yu Hsieh, Yen-Lin Chen, Yi-Chen Yeh, Yi-Hsin Liang, Yu-Li Su, Chiung-Ru Lai, James Chih-Hsin Yang

Source: Journal of Cancer Research and Practice, Vol 11, Iss 1, Pp 18-27 (2024)

Subject Terms: molecular tumor board, next-generation sequencing, taiwan oncology society, taiwan society of pathology, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00050; https://doaj.org/toc/2311-3006

Access URL: https://doaj.org/article/445838d2968349c0869dce108cd349c3

Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

Authors: Charles M. Rudin, Martin Reck, Melissa L. Johnson, Fiona Blackhall, Christine L. Hann, James Chih-Hsin Yang, Julie M. Bailis, Gwyn Bebb, Amanda Goldrick, John Umejiego, Luis Paz-Ares

Source: Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-21 (2023)

Subject Terms: DLL3, Small cell lung cancer, T-cell engager, Antibody-drug conjugate, Tarlatamab, AMG 757, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1756-8722

Access URL: https://doaj.org/article/10e1da2e3d234f1e801863a73f93ec88

Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first‐line EGFR inhibitor resistance in lung cancer

Authors: Yen‐Ting Lin, Chao‐Chi Ho, Wei‐Hsun Hsu, Wei‐Yu Liao, Ching‐Yao Yang, Chong‐Jen Yu, Tzu‐Hsiu Tsai, James Chih‐Hsin Yang, Shang‐Gin Wu, Chia‐Lin Hsu, Min‐Shu Hsieh, Yen‐Lin Huang, Chia‐Ling Wu, Jin‐Yuan Shih

Source: Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)

Subject Terms: EGFR mutation, EGFR‐TKI resistance, next‐generation sequencing, NSCLC, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/16337db479754d2fa1ffefc1d301d9fd

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

Authors: Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki Papadimitrakopoulou

Source: Nature Communications, Vol 14, Iss 1, Pp 1-8 (2023)

Subject Terms: Science

File Description: electronic resource

Relation: https://doaj.org/toc/2041-1723

Access URL: https://doaj.org/article/97023c9e42e0450eab3688b9d4689761

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Authors: Hye Ryun Kim, MD, PhD, Mark M. Awad, MD, PhD, Alejandro Navarro, MD, Maya Gottfried, MD, Solange Peters, MD, PhD, Tibor Csőszi, MD, Parneet K. Cheema, MD, Delvys Rodriguez-Abreu, MD, PhD, Mirjana Wollner, MD, James Chih-Hsin Yang, MD, PhD, Julien Mazieres, MD, PhD, Francisco J. Orlandi, MD, Alexander Luft, MD, PhD, Mahmut Gümüş, MD, Terufumi Kato, MD, Gregory P. Kalemkerian, MD, Yiwen Luo, PhD, Melissa L. Santorelli, PhD, MPH, M. Catherine Pietanza, MD, Charles M. Rudin, MD, PhD

Source: JTO Clinical and Research Reports, Vol 4, Iss 11, Pp 100572- (2023)

Subject Terms: Pembrolizumab, Chemotherapy, Extensive-stage small-cell lung cancer, Health-related quality of life, Patient-reported outcomes, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364323001157; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/0e1816cce869459686df7d5b2f6d1a2d

Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front‐line chemotherapy regimens

Authors: Wei‐Li Ma, Chia‐Chi Lin, Feng‐Ming Hsu, Jang‐Ming Lee, Jin‐Shing Chen, Yen‐Lin Huang, Yih‐Leong Chang, Chin‐Hao Chang, James Chih‐Hsin Yang

Source: Cancer Medicine, Vol 11, Iss 18, Pp 3445-3456 (2022)

Subject Terms: front‐line chemotherapy, overall survival, thymic carcinoma, thymoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/e574cac37ef049b4843c2bd862c774dd

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors

Authors: Ming-Hung Huang, PhD, Jih-Hsiang Lee, MD, Pei-Shan Hung, PhD, James Chih-Hsin Yang, MD, PhD

Source: JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100405- (2022)

Subject Terms: EGFR, EML4-ALK, Lung cancer, EGFR-TKI, ALK inhibitor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364322001291; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/c742730770484fc89bfb187c775337b7

Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma

Authors: Chia-Ling Chang, Min-Shu Hsieh, Jin-Yuan Shih, Yi-Hsuan Lee, Wei-Yu Liao, Chia-Lin Hsu, Ching-Yao Yang, Kuan-Yu Chen, Jih-Hsiang Lee, Chao-Chi Ho, Tzu-Hsiu Tsai, James Chih-Hsin Yang, Chong-Jen Yu

Source: Therapeutic Advances in Medical Oncology, Vol 14 (2022)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1758-8359

Access URL: https://doaj.org/article/1dadd76b237e4da5b667989b7cc5051d

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC

Authors: Yi-Long Wu, MD, Shun Lu, MD, PhD, James Chih-Hsin Yang, MD, PhD, Jianying Zhou, MD, Takashi Seto, MD, Myung-Ju Ahn, MD, PhD, Wu-Chou Su, MD, Noboru Yamamoto, MD, PhD, Dong-Wan Kim, MD, PhD, Jolanda Paolini, MSc, Tiziana Usari, BSc, Laura Iadeluca, PhD, Keith D. Wilner, PhD, Koichi Goto, MD, PhD

Source: JTO Clinical and Research Reports, Vol 3, Iss 10, Pp 100406- (2022)

Subject Terms: Asia, Crizotinib, NSCLC, Phase 2, ROS1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364322001308; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/7369e36175e44454b80a3ac673b3634f

Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan

Authors: Yuh-Min Chen, James Chih-Hsin Yang, Wu-Chou Su, Inn-Wen Chong, Te-Chun Hsia, Meng-Chih Lin, Gee-Chen Chang, Chao-Hua Chiu, Chao-Chi Ho, Shang-Yin Wu, Jen-Yu Hung, Chin-Chou Wang, Tsung-Ying Yang, Chong-Jen Yu

Source: Journal of the Formosan Medical Association, Vol 119, Iss 12, Pp 1817-1826 (2020)

Subject Terms: Monoclonal antibodies, Non-small cell lung carcinoma, Programmed cell death 1 receptor, Safety, Taiwan, Medicine (General), R5-920

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S0929664620300085; https://doaj.org/toc/0929-6646

Access URL: https://doaj.org/article/24167e0b10f44ec788ae98ac291d1fa1

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

Authors: James Chih-Hsin Yang, Martin Schuler, Sanjay Popat, Satoru Miura, Keunchil Park, Antonio Passaro, Filippo De Marinis, Flavio Solca, Angela Märten, Edward S. Kim

Source: Frontiers in Oncology, Vol 12 (2022)

Subject Terms: afatinib, non-small-cell lung cancer, uncommon EGFR mutations, compound mutations, EGFR exon 20 insertions, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2022.834704/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/06285341cf024f7fb6cee27c5cc600a1

Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer

Authors: Wen-Chi Yang, Feng-Ming Hsu, Yu-Hsuan Chen, Jin-Yuan Shih, Chong-Jen Yu, Zhong-Zhe Lin, Szu-Huai Lu, James Chih-Hsin Yang, Ann-Lii Cheng, Sung-Hsin Kuo

Source: Clinical and Translational Radiation Oncology, Vol 22, Iss , Pp 76-82 (2020)

Subject Terms: Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2405630820300215; https://doaj.org/toc/2405-6308

Access URL: https://doaj.org/article/2568329652d64cd6b10b6c3c10da80b0

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer

Authors: Mi Ran Yun, Hun Mi Choi, You Won Lee, Hyeong Seok Joo, Chae Won Park, Jae Woo Choi, Dong Hwi Kim, Han Na Kang, Kyoung‐Ho Pyo, Eun Joo Shin, Hyo Sup Shim, Ross A Soo, James Chih‐Hsin Yang, Sung Sook Lee, Hyun Chang, Min Hwan Kim, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho

Source: EMBO Molecular Medicine, Vol 11, Iss 12, Pp 1-17 (2019)

Subject Terms: acquired resistance, ALK, non‐small cell lung cancer, statin, YAP, Medicine (General), R5-920, Genetics, QH426-470

File Description: electronic resource

Relation: https://doaj.org/toc/1757-4676; https://doaj.org/toc/1757-4684

Access URL: https://doaj.org/article/d4178ca591ff41c1b89ca89a0354a643

Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides

Authors: Shu-Ting Hong, Huaching Lin, Chen-Shen Wang, Chih-Hsien Chang, Anya Maan-Yuh Lin, James Chih-Hsin Yang, Yu-Li Lo

Source: Journal of Nanobiotechnology, Vol 17, Iss 1, Pp 1-20 (2019)

Subject Terms: Afatinib, Epidermal growth factor receptor (EGFR), Nanoparticles, Cell-penetrating peptides, Colorectal cancer, Targeting delivery, Biotechnology, TP248.13-248.65, Medical technology, R855-855.5

File Description: electronic resource

Relation: http://link.springer.com/article/10.1186/s12951-019-0519-6; https://doaj.org/toc/1477-3155

Access URL: https://doaj.org/article/fd10b71ae5534e21b3c64395d04e1c5b

Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unit

Authors: Emily Han-Chung Hsiue, Pei-Lin Lee, Yung-Hsuan Chen, Ting-Hui Wu, Chiao-Feng Cheng, Keng-Man Cheng, Po-Chun Yang, Hsing-Wu Chen, Pei-Yu Lin, Dai-Lung Chiang, Huey-Dong Wu, James Chih-Hsin Yang, Chong-Jen Yu

Source: Journal of the Formosan Medical Association, Vol 118, Iss 6, Pp 995-1004 (2019)

Subject Terms: Medicine (General), R5-920

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S0929664618307071; https://doaj.org/toc/0929-6646

Access URL: https://doaj.org/article/d54747dbc0ce424a9c2e5e87c53df004

459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC

Authors: Matthew Hellmann, Ying Cheng, Toshiaki Takahashi, Gilberto de Castro, M Catherine Pietanza, James Chih-Hsin Yang, Byoung Cho, Rosalyn Juergens, Mustafa Erman, Jessica Bauman, Paul Schwarzenberger, Pingye Zhang

Source: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/2116ff1baf5349cfbe8aac848a2def32

457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC)

Authors: Enriqueta Felip, Jianda Yuan, Lawrence Fong, Charu Aggarwal, Razvan Cristescu, Myung-Ju Ahn, Alexandra Snyder, Matthew Hellmann, Roy Herbst, Martin Gutierrez, Edward Garon, Jong-Seok Lee, Julie Kobie, Matthew Gubens, Daniel Shao Weng Tan, Joanne WY Chiu, James Chih-Hsin Yang, Giovanna Finocchiaro, Alexander Luft, Gregory Landers, Andrea Basso, Hua Ma, John Palcza

Source: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/f606c751f88546b2b65dd38f5eef52da